Kraig Biocraft Laboratories Inc (KBLB): The effect of significant PRs on the mar...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Re: WebSlinger post# 165887

Monday, 08/05/2019 3:07:57 PM

Monday, August 05, 2019 3:07:57 PM

The effect of significant PRs on the market via the OTC is not cost effctive.

Why waste the expense, and the impact of PRs, on the OTC?

Keep Last Read

Next 10 Prev Next

Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/16/2024 09:00:29 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:30:52 PM
Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/10/2024 08:30:30 PM
Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/04/2024 04:15:03 AM
Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/22/2023 09:31:54 PM
Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/16/2023 09:30:34 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:43:51 PM
Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/11/2023 08:30:50 PM

InvestorsHub NewsWire

Only $200 per official company press release!